Kymera Therapeutics (KYMR) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Kymera Therapeutics (KYMR) Net Income towards Common Stockholders Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 116.57% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.12 Bn | - | -5.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.57% |
| Dec 31, 2025 | -22.94% |
| Sep 30, 2025 | -31.51% |
| Jun 30, 2025 | -82.15% |
| Mar 31, 2025 | -35.06% |
| Dec 31, 2024 | -392.43% |
| Sep 30, 2024 | -18.20% |
| Jun 30, 2024 | -8.41% |
| Mar 31, 2024 | -18.64% |
| Dec 31, 2023 | 58.79% |
| Sep 30, 2023 | -22.94% |
| Jun 30, 2023 | 3.62% |
| Mar 31, 2023 | 75.71% |
| Dec 31, 2022 | -2.35% |
| Sep 30, 2022 | 84.09% |
| Jun 30, 2022 | -63.25% |
| Mar 31, 2022 | -1,188.61% |
| Dec 31, 2021 | -168.53% |
| Sep 30, 2021 | -3,284.52% |
| Jun 30, 2021 | -76.28% |